Core Insights - The article highlights the transformation of innovative pharmaceutical products from exhibition items to market-ready goods, emphasizing the role of the China International Import Expo (CIIE) in accelerating this process [1][3][4]. Group 1: Company Background - Roche, a leading global biotechnology company with nearly 130 years of history, has a long-standing relationship with China, dating back to 1926 when it introduced its products through a Shanghai pharmacy [2]. - Roche has been a consistent participant in the CIIE since its inception, viewing it as a vital platform for showcasing innovative products and enhancing connections with customers and government [2][5]. Group 2: Product Development and Market Entry - The innovative drug, Sufuda, was first showcased at the second CIIE and gained significant attention due to its unique treatment mechanism, requiring only a single dose [3][4]. - Following its debut, Sufuda was included in the list of urgently needed foreign clinical drugs and received approval for sale in China within five months, demonstrating the CIIE's impact on product commercialization [3][4]. Group 3: Investment and Future Prospects - Roche announced a significant investment of 2.04 billion RMB to establish a new biopharmaceutical production base in Shanghai, reflecting its commitment to the Chinese market and the potential for growth [5]. - The CIIE has facilitated Roche's transition from an exhibitor to an investor, with expectations for more innovative products to emerge from future expos, continuing to benefit Chinese patients [5].